Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioStem Technologies, Inc. (BSEM)

BioStem Technologies Q2 revenue up 29% from Q1 to $7.9 million; raises 2026 guidance

Mixed Impact 4 of 5 earnings Written later

BioStem Technologies reported second quarter 2026 results on August 12, 2026, with net revenue of $7.9 million, up 29% from $6.1 million in the first quarter but down from $11.0 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $26 million to $29 million, but posted a GAAP net loss of $9.0 million, or $0.52 per share, and cash and cash equivalents fell to $7.0 million at June 30, 2026.

Key points

  • Net revenue of $7.9 million, up 29% from $6.1 million in Q1 2026 and down from $11.0 million in Q2 2025
  • GAAP net loss of $9.0 million, or $0.52 per share, versus net income of $10,613 in Q2 2025; gross margin 61% versus 94% a year earlier
  • Full-year 2026 revenue guidance raised to $26 million to $29 million from $25 million to $29 million
  • Cash and cash equivalents of $7.0 million at June 30, 2026, compared with $13.7 million at the end of Q1 2026

The filing

CompanyBioStem Technologies, Inc. (BSEM)
Form8-K, current report
Filed with the SECAug 12, 2026, 5:27 PM ET
Accession number0001193125-26-347211

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.